NA
AMED

Navellier & Associates’s Amedisys AMED Stock Holding History

Navellier & Associates’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-24,311
Closed -$5.95M – 309
2021
Q2 		$5.95M Buy
24,311
+16
+0.1% +$4.2K 0.9% 36
2021
Q1 		$6.43M Buy
+24,295
New +$6.85M 1.16% 24
2019
Q2 		– Sell
-19,784
Closed -$2.44M – 272
2019
Q1 		$2.44M Buy
19,784
+2,226
+13% +$279K 0.38% 71
2018
Q4 		$2.06M Buy
17,558
+10,499
+149% +$1.24M 0.35% 72
2018
Q3 		$882K Buy
+7,059
New +$780K 0.11% 157

Other funds holding AMED

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Navellier & Associates's AMED Position: Q3 2021 in Review

Navellier & Associates sold out of Amedisys (AMED) in Q3 2021, closing a stake of 24,311 shares — an estimated $5.95M sold.

Navellier & Associates first reported a position in AMED in Q3 2018 and held it in 5 quarters. The position peaked at $6.43M in Q1 2021. 352 funds tracked by Wall St. Rank hold AMED as of Q3 2021.

  • Navellier & Associates reported no remaining Amedisys position as of Q3 2021 after selling out during the quarter.
  • Navellier & Associates sold 24,311 Amedisys shares in Q3 2021, an estimated $5.95M.
  • Navellier & Associates first reported a position in Amedisys in Q3 2018 and held it in 5 quarters.
  • Navellier & Associates's Amedisys position peaked at $6.43M in Q1 2021.
  • 352 funds tracked by Wall St. Rank held Amedisys as of Q3 2021.

Based on Navellier & Associates's 13F filing for Q3 2021, filed 28 Oct 2021.